Phio Pharmaceuticals remains a pre-commercial biotechnology entity characterized by a total absence of revenue and an escalating R&D burn rate that reached $2.8 million in 2026Q1. The company's reliance on external capital to fund its clinical-stage programs p...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical
Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762 King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing
Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP announcements King of Prussia, Pennsylvania--(Newsfile Corp. - August 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended June 30, 2026, and provided a business update.
Benchmark PHIO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Phio Pharmaceuticals Corp. (PHIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.00 | $11.62M | -0.69 | — | — | -69.95% | — | |
| $20.81 | $2.2B | -2.92 | 15.58% | -6.93% | -9.96% | — | |
| $71.86 | $10.12B | -5890.16 | 23258.15% | -47.79% | -60.05% | — | |
| $251.65 | $33.6B | 108.00 | 65.19% | 16.82% | 93.61% | — | |
| $12.69 | $1.42B | -3.33 | 16.92% | -672.16% | -57.79% | — | |
| $25.93 | $2.67B | -32.01 | 120.01% | -54.75% | -7.7% | — |
Phio Pharmaceuticals Corp. (PHIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Phio Pharmaceuticals Corp. (PHIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 21, 2026·SEC
May 7, 2026·SEC
Get notified when PHIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Phio Pharmaceuticals Corp. (PHIO) stock FAQ — growth, dividends, profitability & financials explained
Phio Pharmaceuticals Corp. (PHIO) reported a net loss of $12.9M for fiscal year 2025.
Phio Pharmaceuticals Corp. (PHIO) has a return on equity (ROE) of -69.9%. Negative ROE indicates the company is unprofitable.
Phio Pharmaceuticals Corp. (PHIO) had negative free cash flow of $16.2M in fiscal year 2025, likely due to heavy capital investments.
